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Abstract 29 
Background 30 
PREDICT Prostate is an endorsed prognostic model that provides individualised long-term prostate 31 
cancer-specific and overall survival estimates. The model, derived from UK data, estimates potential 32 
treatment benefit on overall survival. In this study we externally validated the model in a large 33 
independent dataset, and compared performance to existing models and within treatment groups. 34 
Methods 35 
Men with non-metastatic prostate cancer and PSA <100 ng/ml diagnosed between 2000 and 2010 in 36 
the nationwide population-based Prostate Cancer data Base Sweden(PCBaSe) were included. Data 37 
on age, PSA, clinical stage, grade group, biopsy involvement, primary treatment and comorbidity 38 
were retrieved. 69,206 men were included with 13.9 years median follow-up. 15-year survival 39 
estimates were calculated using PREDICT Prostate for prostate cancer-specific mortality(PCSM) and 40 
all-cause mortality(ACM). Discrimination was assessed using Harrell͛s concordance;cͿ-index in R. 41 
Calibration was evaluated using cumulative available follow-up in Stata (TX, USA).  42 
Results  43 
Overall discrimination of PREDICT Prostate was good with c-indices of 0.85(95% CI 0.85-0.86) for 44 
PCSM and 0.79(95% CI 0.79-0.80) for ACM. Overall calibration of the model was excellent with 45 
25,925 deaths predicted and 25,849 deaths observed.  Within the conservative management and 46 
radical treatment groups c-indices for 15-year PCSM were 0.81 and 0.78 respectively. Calibration 47 
also remained good within treatment groups. The discrimination of PREDICT Prostate significantly 48 
outperformed the EAU, NCCN and CAPRA score for both PCSM and ACM within this cohort overall.  49 
A key limitation is the use of retrospective cohort data. 50 
Conclusions 51 
This large external validation demonstrates that PREDICT Prostate is a robust and generalisable 52 
model to aid clinical decision making. 53 
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  69 
Background 70 
Prostate cancer represents a growing burden on health care globally, with increasing numbers and 71 
proportions of men presenting with non-metastatic prostate cancer (PCa) (1). Alongside this, there 72 
has been increased confidence in the use of conservative management (active surveillance and 73 
watchful waiting) (2). Understanding disease prognosis to guide treatment decision-making is 74 
therefore of great importance. However, until recently no high-quality individualised model for 75 
survival existed.  76 
Using data from over 10,000 UK men, we have previously published an individualised prognostic 77 
model for cancer-specific and overall survival called ͚PREDICT Prostate’ (3). PREDICT Prostate 78 
(available online(4)) provides cancer-specific and overall percentage survival estimates for up to 15 79 
years and has been endorsed by the National Institute for Health and Care Excellence (NICE)(5).  To 80 
maximise usability, it uses routinely-available clinico-pathological data (age, PSA, grade, stage, 81 
biopsy involvement, treatment type and comorbidity).  It represents real-world data from a non-82 
screened, primary diagnostic cohort, including a significant number of men treated conservatively. 83 
Crucially, the model also allows adjustment for competing mortalities by incorporating both cancer-84 
specific and non-cancer survival outcomes to contextualise the diagnosis as part of a decision-aid.   85 
Internal validation and accuracy within a small external population were promising during model 86 
development (3). However, external validation in independent cohorts, ideally in a different location, 87 
is vital to demonstrate generalisability and accuracy of a multivariable prognostic model (6).  88 
The Prostate Cancer database Sweden (PCBaSe) is one of the largest and most comprehensive 89 
prostate cancer cohorts world-wide and is well-suited for external validation of PREDICT Prostate (7). 90 
The aim of this study was to validate PREDICT Prostate and compare performance to existing 91 
models. 92 
Methods 93 
Source of data 94 
Data from PCBaSE  3.0 were used, according to a pre-specified project outline (Additional File 2). 95 
PCBaSe was created by the combination of the National Prostate Cancer Register of Sweden with 96 
other national healthcare and demographic databases (8). The capture rate of this register is 98% of 97 
all incident prostate cancer cases compared to the Swedish Cancer Registry ʹ to which registration is 98 
mandated by law (9). Cause of death information is updated from the Cause of Death Registry which 99 
captures all deaths in Sweden. The agreement between recorded cause of death and reviewed 100 
medical records has been reported at 86% (95% CI: 85-87%)(10).  101 
 102 
Participants and predictors  103 
We included men within PCBaSe diagnosed with PCa between January 1st 2000 and 31st December 104 
2010, with no evidence of metastatic disease and prostate specific antigen (PSA) <100ng/ml. Cases 105 
were censored at death, migration or 31st December 2016, whichever event occurred first. Data 106 
were available for 82,936 men. Outcome events were ͚PCa death͛ or ͚anǇ cause death͛ from which 107 
͚non-PCa death͛ was derived. Intact data were required for variables mandatory within the model: 108 
age, PSA, T-stage, histological grade-group, primary treatment type and comorbidity. This led to the 109 
exclusion of 13,730 (16.6%) cases, leaving a final analysable dataset of 69,206 (Table 1). Missing data 110 
were most abundant for histological grade group (n=8117), as primary and secondary Gleason grade 111 
were not always registered. Data were also missing on PSA (n=2124), T-stage (n=1364), age (n=4) 112 
and primary treatment (n=3960). Some men had missing data for more than one variable. All 113 
variables were determined at the time of diagnosis. Biopsy characteristics are an optional variable in 114 
the PREDICT Prostate model, therefore missing data on proportion of positive cores ([PPC] = number 115 
of cores with any cancer/number of cores taken) were tolerated. We also re-tested the value of PPC 116 
to predict PCa death in a subgroup with intact biopsy information (n=44,163) using the same method 117 
as previously (3). Primary treatment was defined as the radical treatment received up to 12 months 118 
after the date of diagnosis, or conservative management. The same definition of comorbidity was 119 
used as in the model development: the combination of both Charlson Comorbidity Index of 1 or 120 
greater (excluding PCa) and a hospital admission in the 2 years preceding PCa diagnosis(3).  Up to 121 
2008, the treatment strategies of active surveillance and watchful waiting were reported as 122 
conservative management. After 2008 these strategies were registered as separate entities. We 123 
used conservative management as a treatment strategy also for men diagnosed after 2008, although 124 
a small, well-defined active surveillance group was separately analysed.  125 
 126 
Outcome 127 
The model estimates prostate cancer-specific mortality (PCSM), non-PCa mortality (NPCM) and 128 
overall, or all-cause mortality (ACM), counted from the time of diagnosis. It provides estimates 129 
following conservative management and radical treatment (by either radical prostatectomy or 130 
radiotherapy). 131 
Statistical analysis methods 132 
Beta coefficients for each prognostic factor in the model were applied to derive prognostic indices 133 
for PCSM and NPCM for each patient. These were used in combination with the model͛s baseline 134 
hazard functions and time-at-risk to create individual estimates of unadjusted PCSM and NPCM over 135 
15 years.  These estimates were adjusted for the competing risks between the two causes of death 136 
to generate ACM estimates. To assess discrimination, 15-year estimates were generated͘ Harrell͛s 137 
concordance index (c-index) was then applied using the ͚Hmisc͛ package in R (11).  Discrimination 138 
using PREDICT Prostate was compared to the EAU and NCCN stratification systems, and the UCSF 139 
CAPRA score (12-14). Sub-classification of stage T2 was not available; therefore T2 was assumed to 140 
be T2a for the sake of these classifications. When PPC was unknown, it was assumed to be <34% in 141 
the CAPRA model. Adjusted predictions of cumulative PCSM, NPCM and ACM were generated using 142 
available follow-up for assessment of model calibration. Calibration was assessed using a Chi-square 143 
goodness of fit (GOF) across quintiles of risk using the method of May and Hosmer(15). Calibration 144 
was also assessed within treatment sub-groups. All data analyses were performed in StataΡ ϭϰ, 145 
unless otherwise stated above. 146 
Results 147 
Participants  148 
69,206 men were included with 13.9 years median follow-up. The Swedish population attributes at 149 
baseline are compared to the UK model development cohort in Table 1. Patient characteristics were 150 
similar in both cohorts, with a larger proportion of grade group 1 disease in the Swedish cohort. A 151 
larger proportion of men underwent surgery as opposed to radiotherapy in the Swedish cohort, and 152 
smaller proportion were treated with primary androgen deprivation therapy in this time period. 153 
Breakdown of the patients by risk groups is reported in Additional File 1: Table S1. 154 
 155 
Model performance 156 
Overall discrimination of PREDICT Prostate was very good with C-indices 0.85 (95% CI 0.85-0.86) for 157 
PCSM and 0.79 (95% CI 0.79-0.79) for ACM (Table 2). Overall calibration of the model was excellent 158 
with 25,925 deaths predicted and 25,849 deaths observed in PCBaSe. This equates to an overall 159 
observed:expected (O:E) ratio of 1:1.003. Calibration across quintiles of risk is shown in Figure 1 and 160 
Additional File 1: Table S2. Although the O:E ratio for any-cause death was very close to 1, expected 161 
numbers of PCa deaths were slightly higher than observed (O:E 0.897) , and expected numbers of 162 
non-PCa deaths were lower than observed (O:E 1.060), particularly in the highest risk quintiles 163 
which.  164 
 165 
Treatment Subgroups  166 
Overall, 20,384 men underwent conservative management and 32,842 received radical treatment.  167 
Within these groups c-indices remained good, with c-index for 15-year PCSM 0.81 (95%CI 0.80-0.82) 168 
for conservative management and 0.78 (95% CI 0.77-0.80) for radical treatment (Table 2).  169 
Among men on well-defined active surveillance, C-indices were further improved at 0.88 for PCSM 170 
and 0.75 for ACM (Additional File 1: Table S3). Calibration also remained good within treatment 171 
groups with differences between observed and predicted numbers of overall deaths 1.4%, 2.2% and 172 
3.1% among men who received active surveillance, radiotherapy, and prostatectomy, respectively 173 
(Table 3). The model overestimated PCSM and underestimate NPCM within the subgroup which 174 
received androgen deprivation monotherapy by as much as 8% ʹ but remained within 2% for overall 175 
death (Table 3).  176 
Comparison to existing models 177 
PREDICT Prostate significantly outperformed the comparator models when predicting ACM, both 178 
overall and within every major treatment sub-group (Table 2 + Additional File 1: Table S3). 179 
Discriminatory performance was significantly better for PCSM overall (Additional File 1: Table S4). 180 
Across all treatment sub-groups, the model outperformed the 3-stratum EAU risk categories. 181 
Improvements in discrimination failed to reach significance for PCSM in some comparisons with the 182 
NCCN and CAPRA score, but in only one incidence was the c-index better for one of these 183 
comparator models (CAPRA score for PCSM among RP patients, Additional File 1: Table S3). 184 
Biopsy parameter sub-analysis 185 
Biopsy parameterisation using percentage of positive cores (PPC) was re-explored within a group of 186 
44,163 men who had this information registered (Additional File 1). Inclusion of biopsy 187 
characteristics did not significantly alter the discriminatory performance of the model (Additional 188 
File 1: Table S4 & Table S5); either using a dichotomous 50% percentage of cores cut-off or PPC as a 189 
continuous variable. Inclusion of biopsy information did improve calibration across lower-risk 190 
quintiles of risk for PCSM. Calibration for any-cause death however was unchanged regardless of 191 
inclusion of biopsy information (Additional File 1: Table S6 & Figure S1). 192 
 193 
 194 
  195 
Discussion  196 
 197 
In this large external validation cohort we demonstrated that PREDICT Prostate is a robust and 198 
generalisable long-term prognostic model. In analysis of an independent cohort, ten times larger 199 
than the original cohort, discriminatory accuracy and calibration was good. This also remained true 200 
within treatment groups, particularly in men managed conservatively or by radical therapy.  201 
Conveying information to an individual about their disease prognosis within their own context of 202 
competing mortality has historically been an imprecise exercise with little objective data available. 203 
Most current prognostication is based on stratification groups of the cancer itself and discussions 204 
with clinicians who may be conflicted towards a particular treatment (16-18).  PREDICT Prostate was 205 
conceived to address this gap in clinical need and standardise the decision-making process (3) and 206 
has shown promise to positively influence clinical decision-making(19). It is built around long-term 207 
actual survival data and has been designed to address all AJCC criteria (6).  208 
In the model development study, C-indices were 0.84 for PCSM and 0.77 for ACM within the UK 209 
validation cohort (3). In the original study external validity was also assessed within a Singaporean 210 
cohort. However, this cohort was small (n=2,546) and follow-up was quite short (5.1 years). Here we 211 
show in a cohort of >69,000 men with longer median follow-up that our c-indices were actually 212 
improved to 0.85 for PCSM and 0.79 for ACM with excellent calibration. We did note a marginal 213 
overestimation of PCSM, which was contrary to the slight underestimation we had observed in the 214 
Singapore external validation in the original paper (3). Given that the model is very well calibrated 215 
for ACM, this apparent overestimation of PCSM and (corresponding underestimation of NPCM) is 216 
likely to be a result of differences in cause of death classification, reporting or recording practices. 217 
ACM is the key outcome of interest, and a more unequivocal endpoint, against which this model 218 
performs very well.  219 
When compared to existing models, PREDICT Prostate consistently out-performed the three-stratum 220 
risk classification system used in the EAU, D͛Amico and NICE stratification criteria (13, 17, 20). We 221 
recognise that comparisons against these risk stratification criteria are limited, and that they are not 222 
designed to be prognostic nomograms, however, they are widely used in clinical practice to inform 223 
treatment decisions. Benefits of PREDICT were also seen against the NCCN and CAPRA scores, which 224 
add more granularity but ultimately retain a grouping system rather than individual estimates (13, 225 
14). For the outcome of PCSM, the CAPRA score did perform similarly well for some treatment 226 
groups, particularly in men treated with prostatectomy. This is unsurprising, as the model was 227 
originally built around prostatectomy patients (21). It should be noted, that PREDICT Prostate is not 228 
a treatment-specific tool, therefore by assessing discrimination within treatment sub-groups its 229 
discriminatory performance will inevitably be reduced.  Nonetheless, PREDICT Prostate performed 230 
significantly better in predicting ACM and PCSM in most treatment groups. We also confirmed that 231 
adding in biopsy data to the model improved the performance though this effect was marginal in 232 
addition to the other variables already included. Using PPC as a continuous variable maximises use 233 
of prognostic information, and this parameterisation did lead to marginally superior discrimination 234 
for ACM. 235 
The primary utility of PREDICT Prostate will be in men for whom conservative management and 236 
radical treatment might both be appropriate options, for whom the decision is most difficult.  237 
Abundant literature demonstrates that decision aids contribute to more knowledgeable and 238 
informed patients and that they can improve clinician-patient communication (22, 23). Therefore, 239 
the model may have wide potential applications in informing patient, clinician and multi-disciplinary 240 
team decision-making to reduce both over and under-treatment. Formal clinical impact assessments 241 
are also crucial to show face and functional validity and these are underway with PREDICT Prostate 242 
(24) Future research endeavours could assess what impact the use of the model might have on 243 
actual treatment practices and compare this model with prognostic biomarkers, or radiological 244 
prognosticators. Over time, additional parameters can be incorporated into this base model, or the 245 
model itself be updated, should new variables be shown to have independent prognostic effects 246 
(25).  247 
More recent efforts in prognostic tools have sought to utilise novel genomic or biological markers to 248 
generate prognostic estimates. However, most established genomic tools such as Prolaris CCP and 249 
Oncotype DX GPS have predominantly been tested against shorter-term outcomes or in treatment 250 
specific cohorts (26, 27). Where they have been assessed against PCSM, concordance has been very 251 
similar to our model - for example the Decipher genomic classifier alongside CAPRA showed an AUC 252 
of 0.78 (95%CI 0.68-0.87) for 10-year PCSM following prostatectomy (28). Direct comparison with 253 
PREDICT Prostate is not possible without a head to head or combined study, but the value of such 254 
expensive tests do need to be re-assessed in the context of optimised clinical multivariable models 255 
(29).  In this context we would welcome collaborations or independent studies on the value of 256 
adding genomic classifiers to future iterations of PREDICT Prostate. 257 
This study has numerous strengths, given the large sample size, long follow-up and high 258 
completeness of data in PCBaSe(30). However, we recognise limitations inherent to using registry 259 
data. 17% men were excluded due to missing data and we cannot exclude this introducing some 260 
bias. A large proportion of men within this validation dataset had low grade disease, such that PCa 261 
mortality rates were relatively low which may affect discriminatory performance.  Men diagnosed 262 
within the inclusion period may also not be representative of contemporary practice with changes in 263 
PCa diagnosis and treatment. For instance, we recognise that primary hormone therapy is now rarely 264 
used in the context of non-metastatic PCa, hence we included subgroup analyses within other 265 
treatment groups. We also appreciate that multi-modal therapies are increasingly used in higher risk 266 
cases, which we were not able to assess in this study due to the inclusion dates, and data availability 267 
limitations of our datasets.  Another particular concern is the lack of information from magnetic 268 
resonance imaging (MRI).  However, the current focus for MRI is on tumour-detection rather than 269 
prognostication and it is unknown if MRI lesion characteristics (Likert or PIRAD scoring) have any 270 
bearing on survival. Our model also cannot account for subsequent transitions to different 271 
treatments. However, in our UK dataset, conversions to active treatment were less than 6% across 272 
total follow-up (3). We also recognise the lack of T-stage sub-classification, which is a key parameter 273 
in 2 of the existing models we made comparisons to. However, it is accepted that T-stage is often 274 
inaccurately assigned in localised disease (31). We also recognise that other endpoints of interest 275 
exist, particularly development of metastases and commencement of hormone therapy. The model 276 
is untested against these endpoints, but calibrated against the more robust endpoint of death. 277 
A key issue going forward is the validation of this model in non-Caucasian and screened populations. 278 
Although the original paper re-tested the model in Singaporean men, PREDICT Prostate remains 279 
untested in men of African descent or other ethnicities. Independent validations within screened 280 
populations, and within other prospectively collected or randomised datasets, would also be helpful 281 
and should be encouraged.  Finally, we recognise that other nomograms are available, against which 282 
direct comparisons would be very insightful. These were not possible within the design of this study, 283 
or the limitations of this data, particularly with regards to comorbidity.  284 
Conclusions 285 
This large external validation demonstrates the robustness of PREDICT Prostate. PREDICT Prostate, 286 
available as a free-to-use web tool (4), has the potential to significantly improve shared decision-287 
making for PCa management, particularly the choice between conservative management and radical 288 
treatment. Further, independent external validations are encouraged, especially in populations of 289 
different ethnicities.  290 
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  428 
Tables and legends 429 
 430 
  
UK Model 
Development 
Cohort 
Sweden PCBase 
Cohort 
Total Subjects 7,063  69,206  
Time at risk (years) 58,138  589,733  
Median follow-up (years)  9.8 
Range 
0-16 
 
13.9 
Range 
0-17 
Age (mean, SD) 69.9 8.34 68.8 8.83 
PSA (mean, SD) 18.5 17.5 15.7 17.0 
Gradegroups  %  % 
1 2317 32.8 36992 53.5 
2 2125 30.1 14015 20.3 
3 1057 15.0 7774 11.2 
4 710 10.1 6345 9.2 
5 854 12.1 4080 5.9 
T-stage     
1 3761 53.2 35700 51.6 
2 2270 32.1 22478 32.5 
3 977 13.8 10295 14.9 
4 55 0.8 733 1.1 
Primary Treatment     
Radical Prostatectomy 995 14.1 20936 30.3 
Radical Radiotherapy 2457 34.8 11906 17.2 
Androgen Deprivation Monotherapy 2226 31.5 15980 23.1 
Conservative Management 1385 19.6 20384 29.5 
Comorbidity     
No recorded comorbidity 6363 90.1 62173 89.8 
ComorbiditǇ ;CharlsonшϭͿ 700 9.9 7033 10.2 
10 year outcomes:     
PCa deaths 712  6993  
Non PCa deaths 1555  15122  
Any-cause death 2267  22115  
Overall outcomes:     
PCa deaths 846  8151  
Non PCa deaths 1829  18003  
Any-cause death 2675  26154  
Crude PCS mortality rate (per patient year) 1.46  1.38  
Annual overall mortality rate (per patient 
year) 4.60  4.43  
Table 1. Baseline cohort characteristics in the original UK model development cohort and Prostate 431 
Cancer database Sweden (PCBaSe) cohort. (PCa = prostate cancer SD= standard deviation NA = Not 432 
available) 433 
 434 
 435 
Table 2 ʹ Discrimination of PREDICT Prostate (PREDICT) within treatment subgroups and comparison 436 
to other existing tools. (EAU = European Association of Urology criteria, NCCN = National Cancer 437 
Care Network criteria, CAPRA = UCSF Cancer of the prostate risk assessment criteria, SD = standard 438 
deviation) 439 
 440 
 441 
  PCa Death  
Non-PCa 
death  Any cause death  
 n Obs Pred 
% 
Diff Obs Pred 
% 
Diff Obs Pred 
% 
Diff 
͚Active 
surveillance͛ 6224 195 191 0.06 850 940 1.44 1045 1131 1.38 
͚WatchfƵl 
ǁaiting͛ 2745 239 198 1.49 942 915 0.98 1181 1112 2.51 
   
PCSM 
 
Overall 
 
 
N Tool C-index SD p C-index SD p 
Conservative 
Management 
20384 PREDICT 0.810 0.010 
 
0.740 0.0057 
 
 
20384 EAU 0.746 0.0115 <0.001 0.636 0.0061 <0.001 
 
20384 NCCN 0.760 0.0118 <0.001 0.643 0.0063 <0.001 
 
20384 CAPRA 0.765 0.0125 <0.001 0.643 0.0064 <0.001 
Radical 
Treatment 
32842 PREDICT 0.784 0.0122 
 
0.670 0.0077 
 
 
32842 EAU 0.742 0.0113 <0.001 0.606 0.0077 <0.001 
 
32842 NCCN 0.769 0.0106 0.063 0.617 0.0081 <0.001 
 
32842 CAPRA 0.780 0.0116 0.475 0.625 0.0082 <0.001 
Overall 69206 PREDICT 0.852 0.0038 
 
0.792 0.0028 
 
Other 
conservative  11415 1358 1373 0.13 4906 4535 3.25 6264 5908 3.12 
Radical 
prostatectomy 20936 550 703 0.73 1919 2403 2.31 2469 3107 3.05 
Radiotherapy 8953 737 560 1.94 1591 1594 0.03 2318 2155 2.18 
ADT 15980 4809 5798 6.19 7215 5993 7.65 12024 11792 1.45 
 442 
Table 3 ʹ Calibration of PREDICT Prostate mortality estimates with observed numbers of deaths 443 
within treatment groups  444 
Figure legends 445 
Figure 1  446 
Calibration curves demonstrating observed and expected 15-year probability of death across 447 
quintiles or risk for prostate cancer (PCa) death (left), non-PCa death (centre) and any cause death 448 
(right). 449 
 450 
 451 
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